Inhibitor Therapeutics appoints Michelle Yanez as director, forms Scientific Advisory Board

Inhibitor Therapeutics, Inc.

Michelle Yanez appointed as independent director and Audit Committee member, effective Oct 13, 2023.
Company creates SAB to advise on clinical development; Dr. Elizabeth Billingsley named chairperson.
Consulting agreement with Dermapharm Consulting LLC (Dr. Billingsley) at $600/hour for clinical trial support.

item 5.02 item 5.03 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Michelle Yanez

Director

INTI · Inhibitor Therapeutics, Inc.

Effective: 2023-10-13
Filed: October 18, 2023, 7:59 PM ET

On October 13, 2023, the Board of Directors (the “ Board ”) of Inhibitor Therapeutics, Inc. (the “ Company ”) appointed Michelle Yanez to fill one of the vacancies of the Board.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Michelle Yanez was appointed as Director at Inhibitor Therapeutics, Inc..

Action: appointed
Role: Director

Exact text from the filing

On October 13, 2023, the Board of Directors (the “ Board ”) of Inhibitor Therapeutics, Inc. (the “ Company ”) appointed Michelle Yanez to fill one of the vacancies of the Board.

View on SEC.gov

Inhibitor Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-258156

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.